Full video transcriptClick to expand
Auto-generated transcript of @alllexlintonnn's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:02Brother what's that what's that brother?
GLP-1 drugs called 'disgusting': separating fear from fact
Quick answer
GLP-1 receptor agonists including semaglutide and tirzepatide are FDA-approved for chronic weight management and type 2 diabetes, with robust phase 3 trial data showing 15-21% mean body weight reductions over 68-72 weeks in appropriate patient populations. Common adverse effects are primarily gastrointestinal and tend to diminish after the titration period, though they affect a substantial minority of users. These medications require individualized clinical assessment, ongoing monitoring, and are not appropriate as unsupervised self-administered treatments.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs called 'disgusting': separating fear from fact, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 drugs called 'disgusting': separating fear from fact is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 drugs called 'disgusting': separating fear from fact" from Alexandria Linton 🕊️. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists including semaglutide and tirzepatide are FDA-approved for chronic weight management and type 2 diabetes, with robust phase 3 trial data showing 15-21% mean body weight reductions over 68-72 weeks in appropriate patient populations.
The reason this review is not generic is the source wording and the canonical claim label "glp1 disgusting." In this clip, the useful excerpt is: "Brother what's that what's that brother?" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
GLP-1 receptor agonists including semaglutide and tirzepatide are FDA-approved for chronic weight management and type 2 diabetes, with robust phase 3 trial data showing 15-21% mean body weight reductions over 68-72 weeks in appropriate patient populations.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists including semaglutide and tirzepatide are FDA-approved for chronic weight management and type 2 diabetes, with robust phase 3 trial data showing 15-21% mean body weight reductions over 68-72 weeks in appropriate patient populations. Common adverse effects are primarily gastrointestinal and tend to diminish after the titration period, though they affect a substantial minority of users. These medications require individualized clinical assessment, ongoing monitoring, and are not appropriate as unsupervised self-administered treatments.
- Semaglutide 2.4mg produced 14.9% mean body weight loss versus 2.4% with placebo over 68 weeks in STEP 1 (Wilding et al., 2021, NEJM).
- Tirzepatide 15mg produced 20.9% mean body weight loss over 72 weeks in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), making it among the most effective pharmacological options available.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Semaglutide 2.4mg produced 14.9% mean body weight loss versus 2.4% with placebo over 68 weeks in STEP 1 (Wilding et al., 2021, NEJM).
- Tirzepatide 15mg produced 20.9% mean body weight loss over 72 weeks in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), making it among the most effective pharmacological options available.
- The SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in obese or overweight adults with established cardiovascular disease (Lincoff et al., 2023, NEJM).
- Nausea affects roughly 44% of semaglutide users but is largely transient and mitigated by slow titration protocols used in clinical settings.
- Compounded semaglutide is not FDA-approved and is not equivalent to brand-name Wegovy or Ozempic from a regulatory or quality-assurance standpoint.
- Facial fat loss on GLP-1 therapy reflects generalized weight loss physiology, not a drug-specific mechanism, and is consistent with what occurs after any significant weight reduction.
- GLP-1 therapy requires individualized clinical assessment. Risk-benefit profiles differ substantially across patient populations and cannot be generalized from viral anecdotes.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What's this video probably claiming?
Based on the caption 'Disgusting' and the GLP-1 category tag, this video almost certainly falls into one of the most common TikTok patterns around semaglutide and tirzepatide content: either a visceral reaction to side effects (think: nausea, vomiting, what the internet has dubbed 'Ozempic face'), a moral panic about people using weight-loss drugs as a shortcut, or footage of compounded semaglutide vials meant to shock viewers. With 2.1 million views, the emotional hook clearly worked. The creator likely leans into disgust as a framing device, whether that's aimed at pharmaceutical companies, the aesthetics of injection use, or the broader cultural moment around GLP-1 drugs. What we rarely see in these videos is engagement with the actual clinical literature, the patient populations these drugs were designed for, or any nuance about risk-benefit tradeoffs in people with obesity or type 2 diabetes.
What does the science actually show?
GLP-1 receptor agonists have a legitimate and well-documented clinical record. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 15mg produced a mean body weight reduction of 20.9% over 72 weeks in adults with obesity, without diabetes. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg subcutaneously weekly produced 14.9% mean weight loss over 68 weeks versus 2.4% with placebo. These are not trivial numbers. The SELECT trial (Lincoff et al., 2023, NEJM) added cardiovascular outcome data showing semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease. Side effects are real, particularly gastrointestinal ones, with nausea reported in roughly 44% of semaglutide users in STEP 1. That deserves honest conversation. But 'disgusting' is not a clinical framework.
Where does the social media noise diverge from clinical reality?
The gap between TikTok GLP-1 discourse and clinical reality is significant. Online, the dominant narratives tend to cluster around extreme anecdotes: people who vomited for weeks, lost muscle mass, or developed what commenters call 'Ozempic face' (facial fat loss creating a gaunt appearance). These things do happen. But the framing consistently strips out context. Muscle loss, for instance, is a concern with rapid weight loss by any method, and resistance training plus adequate protein intake during GLP-1 therapy can meaningfully attenuate lean mass loss, as suggested by data from Wilding et al. and subsequent commentary in Obesity Reviews. 'Ozempic face' is not a recognized clinical term and mostly reflects what happens when someone loses 15-20% of their body weight quickly. The drug is not selectively destroying facial tissue. Social media also conflates compounded semaglutide with brand-name Wegovy or Ozempic, which are not the same products and carry different regulatory standing. FormBlends does not treat these as equivalent.
What should you actually know?
If a video is making you feel disgusted by GLP-1 drugs without giving you data, that is a manipulation, not information. Here is what is actually worth knowing. GLP-1 receptor agonists are approved by the FDA for specific indications, require medical supervision, and are not appropriate for everyone. Side effects are common, especially early, and include nausea, diarrhea, constipation, and vomiting. Rare but serious risks include pancreatitis and, in rodent studies (not confirmed in humans at therapeutic doses), thyroid C-cell tumors. The risk-benefit calculus genuinely differs between someone with a BMI of 40 and cardiovascular disease versus someone seeking cosmetic weight loss. No responsible clinician treats those situations identically. Before reacting to a 60-second video designed to provoke emotion, it is worth asking: who is the creator, what are their credentials, and are they citing anything other than their own reaction? Disgust is a feeling. Clinical decision-making requires more than that.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Alexandria Linton 🕊️ · TikTok creator
2.1M views on this video
Disgusting
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about semaglutide 2.4mg produced 14.9% mean body weight loss versus 2.4%?
Semaglutide 2.4mg produced 14.9% mean body weight loss versus 2.4% with placebo over 68 weeks in STEP 1 (Wilding et al., 2021, NEJM).
What does the video say about tirzepatide 15mg produced 20.9% mean body weight loss over 72?
Tirzepatide 15mg produced 20.9% mean body weight loss over 72 weeks in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), making it among the most effective pharmacological options available.
What does the video say about the select trial showed semaglutide reduced major adverse cardiovascular events?
The SELECT trial showed semaglutide reduced major adverse cardiovascular events by 20% in obese or overweight adults with established cardiovascular disease (Lincoff et al., 2023, NEJM).
What does the video say about nausea affects roughly 44% of semaglutide users?
Nausea affects roughly 44% of semaglutide users but is largely transient and mitigated by slow titration protocols used in clinical settings.
What does the video say about compounded semaglutide?
Compounded semaglutide is not FDA-approved and is not equivalent to brand-name Wegovy or Ozempic from a regulatory or quality-assurance standpoint.
What does the video say about facial fat loss on glp-1 therapy reflects generalized weight loss?
Facial fat loss on GLP-1 therapy reflects generalized weight loss physiology, not a drug-specific mechanism, and is consistent with what occurs after any significant weight reduction.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Alexandria Linton 🕊️, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.